Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation

被引:15
作者
Cui, Cheng [1 ,2 ,3 ]
Qu, Yuchen [2 ,3 ,4 ]
Sia, Jie En Valerie [2 ,3 ,5 ]
Zhu, Zhu [4 ]
Wang, Yang [6 ]
Ling, Jing [7 ]
Li, Haiyan [1 ,2 ,3 ]
Jiang, Yan [7 ]
Pan, Jie [4 ]
Liu, Dongyang [2 ,3 ,8 ]
机构
[1] Peking Univ Third Hosp, Dept Cardiol, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Drug Clin Trial Ctr, Beijing 100191, Peoples R China
[3] Peking Univ Third Hosp, Ctr Clin Med Res, Inst Med Innovat & Res, Beijing, Peoples R China
[4] Soochow Univ, Dept Pharm, Affiliated Hosp 2, Suzhou, Peoples R China
[5] Fudan Univ, Sch Pharm, Dept Clin Pharm, Shanghai, Peoples R China
[6] Soochow Univ, Coll Pharmaceut Sci, Suzhou, Peoples R China
[7] Soochow Univ, Dept Pharm, Peoples Hosp Changzhou 1, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China
[8] Peking Univ Third Hosp, Beijing Key Lab Cardiovasc Receptors Res, Beijing, Peoples R China
基金
中国国家自然科学基金; 比尔及梅琳达.盖茨基金会;
关键词
INCORPORATING PATHOPHYSIOLOGICAL CHANGES; HEART-FAILURE PATIENTS; CLINICAL PHARMACOKINETICS; ATRIAL-FIBRILLATION; DRUG-THERAPY; GLYCOPROTEIN; DIGOXIN; EXPRESSION; DISEASE; ADULT;
D O I
10.1007/s40262-022-01184-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objectives P-glycoprotein (P-gp) is one of the most intensely studied transporters owing to its broad tissue distribution and substrate specificity. Existing research suggests that the risk of systemic exposure to dabigatran etexilate (DABE) and digoxin, two P-gp probe substrates in vivo, has significantly increased in elderly patients. We applied a model-based quantitative pharmacological approach to assess aging-related P-gp changes in the Chinese old-elderly population. Methods Population pharmacokinetic (PopPK) modeling was first performed using clinical pharmacokinetic data to explore the effect of age on the pharmacokinetic characteristics of dabigatran (DAB, the active principle of DABE) and digoxin in elderly Chinese patients. Corresponding physiologically based pharmacokinetic (PBPK) models were established to further explain the elevated systemic exposure to these two drugs. Eventually, standard dosing regimens of DABE and digoxin were assessed in Chinese old-elderly patients with chronic heart failure (CHF) with different stages of renal impairment. Results PopPK analysis suggested that age as a covariate had an additional effect on the apparent clearance of these two drugs after correcting for creatinine clearance. PBPK simulation results suggested that disease-specific pathophysiological changes could explain DAB exposure in the young elderly. In the elderly population, 17.1% of elevated DAB exposure remained unexplained, and 25.5% of the reduced P-gp function associated with aging was ultimately obtained using sensitivity analysis. This value was further validated using digoxin data obtained by PBPK modeling. The simulation results suggest that CHF patients with advanced age and moderate-to-severe renal impairment require heightened vigilance for elevated exposure risk during the use of DABE and digoxin. Conclusions Aging might be a significant risk factor for elevated systemic exposure to DAB and digoxin by reducing P-gp-mediated efflux in the Chinese old elderly population.
引用
收藏
页码:1789 / 1800
页数:12
相关论文
共 49 条
[1]   Transporter-enzyme interactions:: Implications for predicting drug-drug interactions from in vitro data [J].
Benet, LZ ;
Cummins, CL ;
Wu, CY .
CURRENT DRUG METABOLISM, 2003, 4 (05) :393-398
[2]   Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences [J].
Bolek, Tomas ;
Samos, Matej ;
Skornova, Ingrid ;
Staniakova, Lucia ;
Stasko, Jan ;
Galajda, Peter ;
Kubisz, Peter ;
Mokan, Marian .
DRUGS & AGING, 2018, 35 (06) :539-544
[3]   P-glycoprotein ABCB1: a major player in drug handling by mammals [J].
Borst, Piet ;
Schinkel, Alfred H. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (10) :4131-4133
[4]   THE PATHOLOGIC PHYSIOLOGY OF CHRONIC BRIGHTS DISEASE - AN EXPOSITION OF THE INTACT NEPHRON HYPOTHESIS [J].
BRICKER, NS ;
MORRIN, PAF ;
KIME, SW .
AMERICAN JOURNAL OF MEDICINE, 1960, 28 (01) :77-98
[5]   Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies [J].
Chen, Yuan ;
Jin, Jin Y. ;
Mukadam, Sophie ;
Malhi, Vikram ;
Kenny, Jane R. .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (02) :85-98
[6]   P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations [J].
Chiu, Catherine ;
Miller, Miles C. ;
Monahan, Renee ;
Osgood, Doreen P. ;
Stopa, Edward G. ;
Silverberg, Gerald D. .
NEUROBIOLOGY OF AGING, 2015, 36 (09) :2475-2482
[7]   Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition [J].
Chu, Xiaoyan ;
Galetin, Aleksandra ;
Zamek-Gliszczynski, Maciej J. ;
Zhang, Lei ;
Tweedie, Donald J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) :788-792
[8]  
Compendium Suisse des Medicaments, 2022, INFORM PROFESSONNELL
[9]   Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects [J].
Cui, Cheng ;
Sia, Jie En Valerie ;
Tu, Siqi ;
Li, Xiaobei ;
Dong, Zhongqi ;
Yu, Zhiheng ;
Yao, Xueting ;
Hatley, Oliver ;
Li, Haiyan ;
Liu, Dongyang .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (07) :2711-2722
[10]   Drug therapy -: Direct thrombin inhibitors [J].
Di Nisio, M ;
Middeldorp, S ;
Büller, HR .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (10) :1028-1040